Talk Digital Health Technologies track
LLS Sponsored Use of a Medical-Grade Wearable into the Beat AML Master Trial—The Oncology Journey
Tue, Feb 4, 2025 · 3:55–4:25 PM EST Rosen Shingle Creek
About this session
LLS/BAML began a sub-study to evaluate shortening the treatment cycle from 28 to 14 days in a Phase 2 trial for AML patients aged 60 and above. The study compares a 28-day schedule (Arm A) with a 14-day schedule (Arm B) of Venetoclax and Azacitidine, focusing on complete remission rates (CRs) and incorporating a wearable medical device. This FDA-cleared device collects physiological data continuously for up to two cycles and is complemented by Patient-Reported Outcomes (PRO) assessments and daily fatigue questionnaires. The study seeks to determine if wearable data aligns with patient-reported outcomes in oncology.
